Cybin Inc. announced the completion of enrollment in its Phase 2 study evaluating CYB004, a proprietary deuterated dimethyltryptamine (DMT) program. This study is for the treatment of Generalized Anxiety Disorder (GAD).
The Phase 2 GAD study successfully enrolled 36 participants to evaluate the safety and efficacy of CYB004 at 12 weeks after the first dose. This milestone marks significant progress in the development of an effective treatment for GAD, which affects millions worldwide.
Cybin reaffirmed its guidance for top-line data from the CYB004 Phase 2 study, which is expected in the first quarter of 2026. The completion of enrollment is a critical step towards bringing this potential new therapy to patients in need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.